Cantitate/Preț
Produs

Probiotic Research in Therapeutics: Volume 5: Metabolic Diseases and Gut Bacteria

Indu Pal Kaur Editat de Kanwaljit Chopra, Mahendra Bishnoi, Kanthi Kiran Kondepudi
en Limba Engleză Hardback – 4 mai 2022
This volume focuses on the potential use of probiotics in treating metabolic disorders such as diabetes mellitus, metabolic acidosis, and gut dysbiosis. Chapters draw an association between gut microbiota and its diversity with metabolic diseases like diabetes, obesity, related liver and gut disorders; gut-brain axis; increased inflammation, and a compromised immune system resulting from these manifestations and scope of intervention with probiotics. Special attention is laid on describing the mechanisms of action of such beneficial effects of probiotic administration. The ability of probiotics to decrease metabolic endotoxemia by restoring the disrupted intestinal mucosal barrier is also included.

The volume is a comprehensive compilation describing the scope and application of probiotic and prebiotic therapy in treating metabolic disorders. Readers will discover how probiotics are not just confined to the microbiology industry but are showing promising results in the medical and pharmaceutical sectors.
Citește tot Restrânge

Toate formatele și edițiile

Toate formatele și edițiile Preț Express
Paperback (1) 119610 lei  6-8 săpt.
  Springer Nature Singapore – 5 mai 2023 119610 lei  6-8 săpt.
Hardback (1) 120198 lei  6-8 săpt.
  Springer Nature Singapore – 4 mai 2022 120198 lei  6-8 săpt.

Preț: 120198 lei

Preț vechi: 146583 lei
-18% Nou

Puncte Express: 1803

Preț estimativ în valută:
23011 23919$ 19078£

Carte tipărită la comandă

Livrare economică 07-21 februarie 25

Preluare comenzi: 021 569.72.76

Specificații

ISBN-13: 9789811684432
ISBN-10: 981168443X
Pagini: 275
Ilustrații: XIV, 275 p. 1 illus.
Dimensiuni: 155 x 235 mm
Greutate: 0.59 kg
Ediția:1st ed. 2022
Editura: Springer Nature Singapore
Colecția Springer
Locul publicării:Singapore, Singapore

Cuprins




Notă biografică

Dr. Indu Pal Kaur is presently working as the Professor and Chairperson at the University Institute of Pharmaceutical Sciences (UIPS). She has more than 25 years of teaching and research experience. Her research forte enhances the performance of small and large biomolecules, including probiotics using active-tailored delivery systems. The emphasis of her work lies in Industrial and clinical translation. She has delivered 50 Invited Talks; published > 145 high impact International publications and 21 book chapters; edited four books and 4 Journal special issues; and > 150 presentations have been made by her research group, with 30 sentenced as best presentations. 

Prof. Kanwaljit Chopra, the former Chairperson of the University Institute of Pharmaceutical Sciences, has prolific experience of 28 years in research and holds distinguished expertise in Neuropharmacology, Diabetes & Metabolic Diseases, Pain, Inflammation, and Menopausal complications. She has more than 215 international and national publications in high-impact journals, acclaimed globally for her research work. She has received eleven prestigious national and international awards. She has fetched grants of over 1.5 Crores from the Government as well as Industry. She has been an active member of National and International societies. Her “Reverse Pharmacology” approach has provided strong leads to the scientific community for the translational potential of various moieties of natural origin. 
Dr. Mahendra Bishnoi is working as Scientist E, Food and Nutritional Biotechnology, National Agri-Food Biotechnology Institute, Mohali. He is presently leading a group of young researchers dedicated to metabolic disorders (obesity and type-2 diabetes) research with a particular focus on nutrition and diet, the development of molecular evidence-based functional foods, and nutraceuticals. His scientific work is well recognized in more than 120 peer-reviewed and high-impact factor scientific journals, with around 4000 citations. Dr. Bishnoi is an Alexander von Humboldt Experienced Fellow, Early and Mid-Career Research (EMCR) fellow of Indian National Science Academy (INSA), Melvin Yahr awardee from World Federation of Neurosciences. 

Dr. Kondepudi is presently working as Scientist-E in the Food & Nutrition Biotechnology Division at National Agri-Food Biotechnology Institute, an autonomous institute under the Department of Biotechnology, Government of India. Dr. Kondepudi is actively working on developing dietary interventions that could beneficially modulate the gut bacteria and could protect from proinflammatory stress underlying many diseases with an overall goal to develop functional foods based on millets and their bioactive ingredients, dietary fibers, prebiotics, probiotics, and other functional ingredients from different plant sources. His group uses rodent models, nutrigenomic and metagenomic approaches for evaluating the efficacy of bioactive ingredients and functional foods.

Textul de pe ultima copertă

This volume focuses on the potential use of probiotics in treating metabolic disorders such as diabetes mellitus, metabolic acidosis, and gut dysbiosis. Chapters draw an association between gut microbiota and its diversity with metabolic diseases like diabetes, obesity, related liver and gut disorders; gut-brain axis; increased inflammation, and a compromised immune system resulting from these manifestations and scope of intervention with probiotics. Special attention is laid on describing the mechanisms of action of such beneficial effects of probiotic administration. The ability of probiotics to decrease metabolic endotoxemia by restoring the disrupted intestinal mucosal barrier is also included.

The volume is a comprehensive compilation describing the scope and application of probiotic and prebiotic therapy in treating metabolic disorders. Readers will discover how probiotics are not just confined to the microbiology industry but are showing promising results in the medical and pharmaceutical sectors.

Caracteristici

Discusses the use of probiotics in type 1 and 2 diabetes, obesity, metabolic endotoxemia, and liver disorders
Explains mechanism of action and growing status of probiotics as therapeutic strategies in metabolic disorders
Describes animal models for pre-clinical studies in metabolic disorders